C&L: PRA International names Baddour CFO

PRA International has named Linda Baddour as executive vice president and CFO. Baddour replaces Matt Bond who resigned to pursue other opportunities.

Transave has named Michio "Mich" Soga as CFO.

Trius Therapeutics announced that Kenneth F. Bartizal, Ph.D. has joined the company as chief development officer.

Arius Research has appointed Robert Gundel as chief scientific officer.

Semafore Pharmaceuticals announced that Ullrich S. Schwertschlag, M.D., Ph.D., has joined the company as chief medical officer.

Cadence Pharmaceuticals has appointed Hazel Aker as senior vice president, general counsel and corporate secretary.

Anadys Pharmaceuticals has promoted Carol G. Gallagher, Pharm. D., to senior vice president of corporate development and commercial affairs.

Martin Tolar, M.D., Ph.D., has joined CoMentis as vice president of strategic and corporate development, a newly created position.

Millennium Pharmaceuticals has named Joseph Bolen, Nancy Simonian and Peter Smith to lead the company's research and development efforts.

Nucryst Pharmaceuticals announced that Edward Gaj Jr. has been appointed vice president, corporate development.

Nventa Biopharmaceuticals has named Richard B. Lai Fatt, Ph.D., as its vice president of corporate development.

Aradigm Corporation has named D. Jeffery Grimes as general counsel and corporate secretary.

Protalix BioTherapeutics has named Professor Ernest Beutler, M.D., to its scientific advisory board.

The following joined Icagen's drug discovery panel: William Catterall, professor and chairman, Department of Pharmacology at the University of Washington; Christine Sang, director of the Translational Pain Research Program at Brigham and Women's Hospital and Harvard Medical School; Cheryl Zimmerman, professor and director of Graduate Studies, Department of Pharmaceutics at the University of Minnesota.

TaiGen Biotechnology announced that current board member, president and CEO, Dr. Ming Chu Hsu, has been unanimously elected as chairman of the company's board of directors.

Introgen Therapeutics shareholders re-elected William H. Cunningham, Ph.D. and S. Malcolm Gillis, Ph.D. who join John N. Kapoor, Charles E. Long, Peter Barton Hutt and David G. Nance as members of the Introgen board of directors. The Introgen board elected David G. Nance to serve as its chairman.

Sally W. Crawford and W. James O'Shea have joined the CombinatoRx board of directors.

Avid Radiopharmaceuticals has added Ernest Mario, Ph.D. to its board of directors.

Somaxon has named Michael L. Eagle as an independent director of the company.

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.